Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HENC Hero Technologies		$0.00	$0.00 ▼ $0.01	N/A	1.2	25,283 shs	N/A
OMGAQ Omega Therapeutics	$0.00	$0.07	$0.00 ▼ $1.69	$166K	0.57	215,590 shs	N/A
RGRX RegeneRx Biopharmaceuticals	$0.00 -99.8%	$0.02	$0.00 ▼ $0.12	N/A	4.64	286 shs	238 shs
VINC Vincerx Pharma	$0.04 -1.3%	$0.05	$0.03 ▼ $17.00	$203K	1.71	585,999 shs	81,852 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HENC Hero Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
OMGAQ Omega Therapeutics	0.00%	0.00%	-95.00%	-97.60%	-99.79%
RGRX RegeneRx Biopharmaceuticals	0.00%	-99.83%	0.00%	0.00%	-85.71%
VINC Vincerx Pharma	0.00%	-2.76%	-15.13%	-29.64%	-99.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HENC Hero Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OMGAQ Omega Therapeutics	2.4799 of 5 stars	3.3	4.0	0.0	0.0	0.0	1.7	1.3
RGRX RegeneRx Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	2.7211 of 5 stars	3.5	3.0	0.0	0.0	1.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HENC Hero Technologies	0.00	N/A	N/A	N/A
OMGAQ Omega Therapeutics	2.50	Moderate Buy	$4.00	133,233.33% Upside
RGRX RegeneRx Biopharmaceuticals	0.00	N/A	N/A	N/A
VINC Vincerx Pharma	3.00	Buy	$40.00	103,259.17% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HENC Hero Technologies	N/A	N/A	N/A	N/A	N/A	N/A
OMGAQ Omega Therapeutics	$3.09M	0.05	N/A	N/A	$1.05 per share	0.00
RGRX RegeneRx Biopharmaceuticals	$80K	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	$10.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HENC Hero Technologies	-$540K	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
OMGAQ Omega Therapeutics	-$97.43M	-$1.33	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RGRX RegeneRx Biopharmaceuticals	-$1.73M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	-$40.16M	-$20.60	N/A	N/A	N/A	N/A	-248.33%	-132.73%	8/19/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HENC Hero Technologies	N/A	N/A	N/A	N/A	N/A
OMGAQ Omega Therapeutics	N/A	N/A	N/A	N/A	N/A
RGRX RegeneRx Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HENC Hero Technologies	N/A	N/A	N/A
OMGAQ Omega Therapeutics	N/A	N/A	N/A
RGRX RegeneRx Biopharmaceuticals	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	2.17	2.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HENC Hero Technologies	N/A
OMGAQ Omega Therapeutics	97.47%
RGRX RegeneRx Biopharmaceuticals	N/A
VINC Vincerx Pharma	44.02%

Insider Ownership

Company	Insider Ownership
HENC Hero Technologies	0.21%
OMGAQ Omega Therapeutics	8.50%
RGRX RegeneRx Biopharmaceuticals	12.60%
VINC Vincerx Pharma	15.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HENC Hero Technologies	1	456.69 million	455.73 million	Not Optionable
OMGAQ Omega Therapeutics	120	55.37 million	50.66 million	Optionable
RGRX RegeneRx Biopharmaceuticals	3	N/A	N/A	Not Optionable
VINC Vincerx Pharma	60	5.23 million	1.89 million	Not Optionable

HENC, VINC, RGRX, and OMGAQ Headlines

Recent News About These Companies

Vincerx Pharma (NASDAQ:VINC) vs. NovaBay Pharmaceuticals (NYSE:NBY) Head to Head Survey

August 8, 2025 | americanbankingnews.com

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...

July 16, 2025 | gurufocus.com

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal

July 16, 2025 | globenewswire.com

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila Times

July 9, 2025 | manilatimes.netM

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar

July 9, 2025 | morningstar.comM

Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance

July 8, 2025 | finance.yahoo.com

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders

July 7, 2025 | globenewswire.com

Vincerx Pharma, Inc. (VINC) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

June 18, 2025 | globenewswire.com

Vincerx Pharma announces plan to delist from Nasdaq

April 18, 2025 | markets.businessinsider.com

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

April 17, 2025 | finance.yahoo.com

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

April 17, 2025 | globenewswire.com

Vincerx's final merger attempt collapses, leaving ADC biotech to wind down

April 9, 2025 | fiercebiotech.comF

Vincerx terminates letter of intent with Global Digital, initiates wind down

April 9, 2025 | markets.businessinsider.com

Financially struggling drugmaker's potential rescue falls apart. It now will wind down

April 9, 2025 | bizjournals.com

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

April 8, 2025 | globenewswire.com

Vincerx Pharma announces non-binding LOI for Qumulus AI combination

March 18, 2025 | markets.businessinsider.com

Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

March 18, 2025 | finanznachrichten.de

Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis

March 18, 2025 | fiercebiotech.comF

Vincerx Pharma Shares Soar on Proposed Merger with Global Digital Holdings

March 18, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HENC, VINC, RGRX, and OMGAQ Company Descriptions

Hero Technologies OTCMKTS:HENC

Hero Technologies Inc. operates as an early-stage cannabis company. It focuses on the provision of BlackBox, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and the cultivation of large flowering plants and create increased harvest efficiencies. The company also intends to offer cannabis genetic engineering farmland for medical and recreational cannabis cultivation, production, distribution, packaging, and retail operations, as well as for dispensaries. The company is based in Dover, Delaware.

Omega Therapeutics OTCMKTS:OMGAQ

$0.0030 0.00 (0.00%)

As of 08/11/2025

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

RegeneRx Biopharmaceuticals OTCMKTS:RGRX

$0.0002 -0.12 (-99.83%)

As of 08/15/2025 09:37 AM Eastern

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Vincerx Pharma NASDAQ:VINC

$0.04 0.00 (-1.28%)

As of 08/15/2025 12:19 PM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time